Antithrombotic therapy for stable coronary artery disease and atrial fibrillation in patients with and without revascularisation: the AFIRE trial

CONCLUSIONS: In high-risk thrombosis patients with a history of prior revascularisation, rivaroxaban monotherapy versus combination therapy demonstrated favourable safety and efficacy outcomes.PMID:38562065 | PMC:PMC10979387 | DOI:10.4244/EIJ-D-23-00396

Source: EuroIntervention - April 2, 2024 Category: Cardiovascular & Thoracic Surgery Authors: Takashi Noda Kotaro Nochioka Koichi Kaikita Masaharu Akao Junya Ako Tetsuya Matoba Masato Nakamura Katsumi Miyauchi Nobuhisa Hagiwara Kazuo Kimura Atsushi Hirayama Kunihiko Matsui Hisao Ogawa Satoshi Yasuda On Behalf Of The Afire Investigators Source Type: research